tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

TAK Stock Latest News

Takeda psoriasis data ‘not clearly better’ than Bristol-Myers’, says Jefferies
The FlyTakeda psoriasis data ‘not clearly better’ than Bristol-Myers’, says Jefferies
4d ago
BMY
TAK
Wells starts Ventyx at Overweight, sees multiple catalysts in next 12-18 months
The FlyWells starts Ventyx at Overweight, sees multiple catalysts in next 12-18 months
4d ago
TAK
VTYX
Ventyx Biosciences price target raised to $65 from $60 at Oppenheimer
The FlyVentyx Biosciences price target raised to $65 from $60 at Oppenheimer
5d ago
TAK
VTYX
Takeda kinase 2 inhibitor meets Phase 2 endpoints in psoriasis patients
The FlyTakeda kinase 2 inhibitor meets Phase 2 endpoints in psoriasis patients
7d ago
TAK
Takeda Pharmaceutical upgraded to Buy from Neutral at BofA
The FlyTakeda Pharmaceutical upgraded to Buy from Neutral at BofA
9d ago
TAK
Kamada CEO issues letter to shareholders
The FlyKamada CEO issues letter to shareholders
10d ago
TAK
KMDA
Hutchmed announces closing of fruquintinib license to Takeda
The FlyHutchmed announces closing of fruquintinib license to Takeda
11d ago
HCM
TAK
Takeda Pharmaceutical presents results from Phase 3 GRAPHITE study
The FlyTakeda Pharmaceutical presents results from Phase 3 GRAPHITE study
1M ago
TAK
Takeda Pharmaceutical: FDA approves sBLA for expanded use of TAKHZYRO
The FlyTakeda Pharmaceutical: FDA approves sBLA for expanded use of TAKHZYRO
2M ago
TAK
Hutchmed Soars on Drug Deal with Takeda
Market NewsHutchmed Soars on Drug Deal with Takeda
2M ago
HCM
TAK
Hutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B
The FlyHutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B
2M ago
HCM
TAK
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Cryoport announces new strategic partnership with Syneos Health
The FlyCryoport announces new strategic partnership with Syneos Health
2M ago
TAK
CYRX
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
The FlyCantor Fitzgerald biotech analyst to hold analyst/industry conference call
2M ago
ALT
TAK
Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
The FlyTakeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
2M ago
TAK
ARWR
Takeda Pharmaceutical reports ‘favorable’ results from Phase 3 TAK-755 trial
The FlyTakeda Pharmaceutical reports ‘favorable’ results from Phase 3 TAK-755 trial
3M ago
TAK
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
The FlyAscendis Pharma price target raised to $177 from $169 at Wells Fargo
3M ago
TAK
ASND
Takeda reports Phase 3 AURORA trial did not meet primary endpoint
The FlyTakeda reports Phase 3 AURORA trial did not meet primary endpoint
3M ago
TAK
Takeda Snaps up Nimbus’ Psoriasis Candidate for $4B
Market NewsTakeda Snaps up Nimbus’ Psoriasis Candidate for $4B
3M ago
TAK
Takeda deal has positive read through for Ventyx, says Piper
The FlyTakeda deal has positive read through for Ventyx, says Piper
3M ago
PFE
TAK
Takeda to acquire NDI-034858 from Nimbus Therapeutics for $4B upfront
The FlyTakeda to acquire NDI-034858 from Nimbus Therapeutics for $4B upfront
3M ago
TAK
Poseida presents preclinical data from P-FVIII-101 gene therapy for hemophilia A
The FlyPoseida presents preclinical data from P-FVIII-101 gene therapy for hemophilia A
3M ago
TAK
PSTX
Takeda Pharmaceutical’s QDENGA approved for use in European Union
The FlyTakeda Pharmaceutical’s QDENGA approved for use in European Union
4M ago
TAK
Seagen announces FDA approval for Adcetris in new indication
The FlySeagen announces FDA approval for Adcetris in new indication
4M ago
TAK
SGEN
Takeda To Sell Consumer Health Unit To Blackstone In $2.3B Deal
Market NewsTakeda To Sell Consumer Health Unit To Blackstone In $2.3B Deal
3y ago
TAK
Blackstone Set To Win Bid For Takeda’s Consumer Health Unit – Report
Market NewsBlackstone Set To Win Bid For Takeda’s Consumer Health Unit – Report
3y ago
TAK
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.